Skip to main content
Equibles
CGON logo

CGON · CG Oncology, Inc.

Track CGON — free

Use CGON with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CGON.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$68.71 +1.33 (+1.97%) At close · Oct 5
Russell 2000 member Rebalance outlook locked
Market Cap
$6.24B
Shares
88.64M
Volume · Oct 5 788.35K Avg daily vol (3M) 896.56K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$68.71 Open$67.60 Day$65.71–68.95 52W close$37.37–80.68 Avg vol 30d934K Short int11.3M · 12.7% float · 17.0d Short vol62% DataJan 2024–Oct 2026 Filing10-Q · Aug 6

Up next

Latest filing: 10-Q
filed Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$6.23M
Trailing 12 months
Net income (TTM)
−$224.38M
Trailing 12 months
Revenue growth YoY
+254.7%
Year over year
Operating margin
-4,056.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-2.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$1.03B
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+15.7%
Year over year · more shares
Price change (1Y)
+69.1%
Trailing year
Short interest
12.7%
Latest settlement · 17.0 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Sell Momentum Neutral Sentiment Bullish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 15.5 · calm Equity put/call 0.59
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg +7%
above
Price vs 50-day avg −7%
below
RSI (14) 42
neutral
MACD trend Negative
52-week position 72%
mid-range
Momentum
relative strength
Neutral
1-month return −8%
trailing
6-month return +2%
trailing
YTD return +65%
this year
Relative strength −9%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $74 › 200d $64 — 50d above 200d
Institutional flow Accumulating
3 of 235 funds reported for Sep 30 · net +21 sh shares · +2 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
12.70% of float · ▼ -1.2% MoM · 17.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
235 holders — near 2-yr high, broad support
Squeeze score 68
elevated · 0–100
Fundamentals
Weak
Revenue growth +255%
Y/Y
EPS growth −48%
Y/Y
Free cash flow $-132.5M
Quant / Vol
risk profile
Very High
Volatility 57%
annualized · 1-yr
Max drawdown −27%
past year
ATR 4.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+7% Bullish
Price vs 50-day avg
−7% Bearish
RSI (14)
42 Neutral
MACD trend
Negative Bearish
52-week position
72% Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $74 › 200d $64 — 50d above 200d
Institutional flow Accumulating
3 of 235 funds reported for Sep 30 · net +21 sh shares · +2 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
12.70% of float · ▼ -1.2% MoM · 17.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
235 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $37 Now $69 · 72% Range high $81
vs 200-day avg +7% vs 50-day avg -7%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CGON
CG Oncology, Inc.
this stock
$6.24B +65.5% +254.7% — 12.7%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +11.1% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -5.9% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +589.1% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
237
% held
111.7%
Reported
3 of 235
Top holder
RTW INVESTMENTS, LP
Held Float
View
Held by Funds
Fund positions
332
View
Short & Settlement
Short Interest Falling
Shares short
11.3M
Days to cover
17.0d
Change
-141.7K sh
View
Short Volume
Short vol %
62%
As of
Oct 5, 2026
Short Total
View
Fails to Deliver
FTD shares
129.9K
Value
$9.9M
As of
Sep 2, 2026
View
Off-Exchange
Off-exchange %
38.9%
Week of
Aug 31, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-161.0M
EPS diluted
$-2.08
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Sep 14, 2026
This year
15
View
Proposed Sales
Value
$2.3M
Shares
30.8K
Filed
Sep 21, 2026
View
Earnings & Events
Webcasts
Last webcast
Sep 14, 2026
View

Performance

5D 20D 120D MTD YTD
CGON -1.3% -8.0% +2.1% -3.1% +65.5%
SPY +1.2% +0.6% +11.6% +1.6% +13.6%
vs SPY -2.5% -8.6% -9.4% -4.7% +51.9%
Key facts CIK 1991792 CUSIP 156944100 13F (30d) 7 filings 7 filers Visit website Investor relations